Status:
UNKNOWN
Ivermectin and Nitazoxanide Combination Therapy for COVID-19
Lead Sponsor:
Tanta University
Conditions:
COVID-19
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
PHASE3
Brief Summary
Research Background and Rationale In December 2019, a new infectious respiratory disease emerged in Wuhan, Hubei province, China. An initial cluster of infections was linked to Huanan seafood market,...
Detailed Description
Selected Drugs Ivermectin has anti-parasitic effect along with anti-viral activity against a broad range of viruses in vitro. Ivermectin was identified as an inhibitor of interaction between the huma...
Eligibility Criteria
Inclusion
- Adult symptomatic patients (18-65 years old), both sexes, and PCR positive in nasopharyngeal sample at admission.
Exclusion
- Abnormal liver function (ALT, AST), chronic kidney disease or dialysis (CrCl\< 30 ml/min), immunocompromised patients taking medication upon screening, subjects on warfarin or dicumarol therapy and those with comorbid condition like hypertension, hypotension, cardiovascular disease, diabetes mellitus, asthma, COPD, seizures, coagulation disorder and malignancy.
- Patients will be also excluded if they had a known allergy to Ivermectin and/or Nitazoxanide, and those with contraindication towards the study medication.
- Pregnant women or women who are breastfeeding will be also excluded.
Key Trial Info
Start Date :
May 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04360356
Start Date
May 1 2020
End Date
December 1 2020
Last Update
April 24 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.